Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study
| Autor: | Di Lauro, L, Pizzuti, L, Barba, M, Sergi, Daniele, Sperduti, I, Mottolese, M, Del Medico, P, Belli, F, Vici, P, De Maria Marchiano, Ruggero, R, Maugeri-Saccà, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Kaplan-Meier Estimate Breast Neoplasms Male Young Adult Metastatic disease Stable Disease Breast cancer Male breast cancer Metastatic disease Chemotherapy Anthracycline-containing regimens Anthracycline- free regimens Settore MED/04 - PATOLOGIA GENERALE Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Anthracycline- free regimens Humans Chemotherapy Neoplasm Metastasis Young adult Aged Retrospective Studies Antitumor activity Anthracycline-free regimens business.industry Endocrine therapy Retrospective cohort study Middle Aged medicine.disease Male breast cancer Anthracycline-containing regimens Treatment Outcome business Research Article |
| Zdroj: | Journal of Experimental & Clinical Cancer Research : CR |
| Popis: | Background The role of chemotherapy in the treatment of metastatic male breast cancer patients remains unknown, and the only available evidence stem from small, retrospective series evaluating outdated drugs and/or regimens. Methods In this retrospective study we evaluated the activity of polychemotherapy, consisting of three-drug (anthracycline-containing and anthracycline-free) regimens, as a first-line therapy for metastatic male breast cancer patients who had received at least one prior endocrine therapy. Results Fifty patients treated between 1978 and 2013 were included in the present analysis. Regarding best response, we recorded 1 (2%) complete response and 27 (54%) partial responses, for an overall response rate of 56% (95% CI, 42.2-69.8). Considering stable disease, the disease control rate was 84%. Median progression-free survival was 7.2 months (95% CI, 5.9-8.5), and median overall survival was 14.2 months (95% CI, 12.2-16.2). Albeit we observed some differences for all the outcomes explored when comparing anthracycline-containing and anthracycline-free regimens, they were not statistically significant. Conclusions Chemotherapy, consisting in both anthracycline-containing and anthracycline-free regimens, showed encouraging antitumor activity in metastatic male breast cancer patients previously treated with endocrine therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|